{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T03:18:46Z","timestamp":1789010326382,"version":"build-2803163510"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T00:00:00Z","timestamp":1733097600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Photodiagnosis and Photodynamic Therapy"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.pdpdt.2024.104430","type":"journal-article","created":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T22:16:36Z","timestamp":1733436996000},"page":"104430","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Comparison of one-year real-world outcomes between red (670 nm) subthreshold micropulse laser treatment and intravitreal aflibercept injection for treatment-na\u00efve diabetic macular edema"],"prefix":"10.1016","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2548-3806","authenticated-orcid":false,"given":"Wataru","family":"Kikushima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukiko","family":"Furuhata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taiyo","family":"Shijo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mizuki","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoichi","family":"Sakurada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daphne","family":"Viel Tsuru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Kashiwagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9735","key":"10.1016\/j.pdpdt.2024.104430_bib0001","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/S0140-6736(09)62124-3","article-title":"Diabetic retinopathy","volume":"376","author":"Cheung","year":"2010","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.pdpdt.2024.104430_bib0002","doi-asserted-by":"crossref","first-page":"556","DOI":"10.2337\/dc11-1909","article-title":"Global prevalence and major risk factors of diabetic retinopathy","volume":"35","author":"Yau","year":"2012","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.pdpdt.2024.104430_bib0003","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1159\/000506747","article-title":"Recent epidemiological status of ocular and other major complications related to diabetes mellitus in Japan","volume":"243","author":"Kume","year":"2020","journal-title":"Ophthalmologica"},{"issue":"2","key":"10.1016\/j.pdpdt.2024.104430_bib0004","doi-asserted-by":"crossref","first-page":"112","DOI":"10.7861\/clinmed.2021-0792","article-title":"Diabetic retinopathy for the non-ophthalmologist","volume":"22","author":"Fung","year":"2022","journal-title":"Clin. Med. (Lond)"},{"issue":"1","key":"10.1016\/j.pdpdt.2024.104430_bib0005","doi-asserted-by":"crossref","first-page":"4488","DOI":"10.1038\/s41598-021-83811-y","article-title":"Outcomes of a 2-year treat-and-extend regimen with aflibercept for diabetic macular edema","volume":"11","author":"Hirano","year":"2021","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.pdpdt.2024.104430_bib0006","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1136\/bjophthalmol-2020-316176","article-title":"Long-term outcomes of treat-and-extend ranibizumab with and without navigated laser for diabetic macular oedema: TREX-DME 3-year results","volume":"105","author":"Payne","year":"2021","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.pdpdt.2024.104430_bib0007","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ajo.2023.07.012","article-title":"KESTREL and KITE Phase 3 Studies: 100-Week Results With Brolucizumab in Patients With Diabetic Macular Edema","volume":"260","author":"Wykoff","year":"2024","journal-title":"Am. J. Ophthalmol."},{"issue":"6","key":"10.1016\/j.pdpdt.2024.104430_bib0008","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.ophtha.2023.12.026","article-title":"Faricimab treat-and-extend for diabetic macular edema: two-year results from the randomized phase 3 yosemite and rhine trials","volume":"131","author":"Wong","year":"2024","journal-title":"Ophthalmology."},{"issue":"2","key":"10.1016\/j.pdpdt.2024.104430_bib0009","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/jdi.12929","article-title":"Clinical preferences and trends of anti-vascular endothelial growth factor treatments for diabetic macular edema in Japan","volume":"10","author":"Sugimoto","year":"2019","journal-title":"J. Diabetes. Investig."},{"issue":"11","key":"10.1016\/j.pdpdt.2024.104430_bib0010","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1016\/j.ophtha.2021.04.027","article-title":"Global prevalence of diabetic retinopathy and projection of burden through 2045: systematic review and meta-analysis","volume":"128","author":"Teo","year":"2021","journal-title":"Ophthalmology."},{"issue":"4","key":"10.1016\/j.pdpdt.2024.104430_bib0011","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.ophtha.2011.12.039","article-title":"Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE","volume":"119","author":"Nguyen","year":"2012","journal-title":"Ophthalmology."},{"issue":"11","key":"10.1016\/j.pdpdt.2024.104430_bib0012","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1016\/j.ophtha.2016.07.032","article-title":"Intravitreal Aflibercept for Diabetic Macular Edema: 148-Week Results from the VISTA and VIVID Studies","volume":"123","author":"Heier","year":"2016","journal-title":"Ophthalmology."},{"issue":"12","key":"10.1016\/j.pdpdt.2024.104430_bib0013","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1001\/archopht.1985.01050120030015","article-title":"Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group","volume":"103","year":"1985","journal-title":"Arch. Ophthalmol."},{"issue":"12","key":"10.1016\/j.pdpdt.2024.104430_bib0014","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.3109\/02713683.2012.705412","article-title":"Intravitreal versus subtenon triamcinolone acetonide injection for diabetic macular edema: a systematic review and meta-analysis","volume":"37","author":"Qi","year":"2012","journal-title":"Curr. Eye Res."},{"issue":"4","key":"10.1016\/j.pdpdt.2024.104430_bib0015","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1097\/IAE.0000000000002921","article-title":"Long-term effect of cystotomy with or without the fibrinogen clot removal for refractory cystoid macular edema secondary to diabetic retinopathy","volume":"41","author":"Imai","year":"2021","journal-title":"Retina"},{"issue":"10","key":"10.1016\/j.pdpdt.2024.104430_bib0016","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1016\/j.ophtha.2014.04.024","article-title":"Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema","volume":"121","author":"Boyer","year":"2014","journal-title":"Ophthalmology."},{"issue":"4","key":"10.1016\/j.pdpdt.2024.104430_bib0017","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s10384-011-0033-3","article-title":"Long-term therapeutic efficacy of the subthreshold micropulse diode laser photocoagulation for diabetic macular edema","volume":"55","author":"Takatsuna","year":"2011","journal-title":"Jpn. J. Ophthalmol."},{"issue":"4","key":"10.1016\/j.pdpdt.2024.104430_bib0018","doi-asserted-by":"crossref","first-page":"274","DOI":"10.2174\/157339912800840523","article-title":"Subthreshold diode micropulse laser photocoagulation (SDM) as invisible retinal phototherapy for diabetic macular edema: a review","volume":"8","author":"Luttrull","year":"2012","journal-title":"Curr. Diabetes. Rev."},{"issue":"5","key":"10.1016\/j.pdpdt.2024.104430_bib0019","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1167\/tvst.9.5.23","article-title":"Comparison of subthreshold 577 and 810 nm micropulse laser effects on heat-shock protein activation kinetics: implications for treatment efficacy and safety","volume":"9","author":"Chang","year":"2020","journal-title":"Transl. Vis. Sci. Technol."},{"issue":"14","key":"10.1016\/j.pdpdt.2024.104430_bib0020","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10143134","article-title":"Subthreshold micropulse laser modulates retinal neuroinflammatory biomarkers in diabetic macular edema","volume":"10","author":"Frizziero","year":"2021","journal-title":"J. Clin. Med."},{"issue":"1","key":"10.1016\/j.pdpdt.2024.104430_bib0021","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12010274","article-title":"Subthreshold micropulse laser for diabetic macular edema: a review","volume":"12","author":"Sabal","year":"2022","journal-title":"J Clin Med."},{"issue":"1","key":"10.1016\/j.pdpdt.2024.104430_bib0022","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s10792-024-02973-6","article-title":"Subthreshold micropulse diode laser treatment in diabetic macular edema: biological impact, therapeutic effects, and safety","volume":"44","author":"Mei","year":"2024","journal-title":"Int. Ophthalmol."},{"issue":"5","key":"10.1016\/j.pdpdt.2024.104430_bib0023","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1007\/s10792-020-01288-6","article-title":"Predictive factors of outcome of selective retina therapy for diabetic macular edema","volume":"40","author":"Yamamoto","year":"2020","journal-title":"Int. Ophthalmol."},{"key":"10.1016\/j.pdpdt.2024.104430_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.pdpdt.2024.104084","article-title":"Six-month results of 577 nm subthreshold micropulse laser therapy in non-center involving diabetic macular edema","volume":"47","author":"Bildirici","year":"2024","journal-title":"Photodiagnosis. Photodyn. Ther."},{"issue":"5","key":"10.1016\/j.pdpdt.2024.104430_bib0025","doi-asserted-by":"crossref","DOI":"10.3390\/jpm11050405","article-title":"Diabetic macular edema treated with 577-nm subthreshold micropulse laser: a real-life, long-term study","volume":"11","author":"Frizziero","year":"2021","journal-title":"J. Pers. Med."},{"issue":"1","key":"10.1016\/j.pdpdt.2024.104430_bib0026","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s40942-020-00268-3","article-title":"Real-life outcomes of subthreshold laser therapy for diabetic macular edema","volume":"7","author":"Passos","year":"2021","journal-title":"Int. J. Retina Vitreous."},{"issue":"1","key":"10.1016\/j.pdpdt.2024.104430_bib0027","doi-asserted-by":"crossref","first-page":"74","DOI":"10.5507\/bp.2022.055","article-title":"Diabetic macular edema treatment with subthreshold micropulse laser - five-year long monitoring","volume":"167","author":"Zavorkova","year":"2023","journal-title":"Biomed. Pap. Med. Fac. Univ. Palacky. Olomouc. Czech. Repub."},{"issue":"11","key":"10.1016\/j.pdpdt.2024.104430_bib0028","doi-asserted-by":"crossref","DOI":"10.3390\/ph14111100","article-title":"Comparison of the 1-year visual and anatomical outcomes between subthreshold red (670 nm) and yellow (577 nm) micro-pulse laser treatment for diabetic macular edema","volume":"14","author":"Kikushima","year":"2021","journal-title":"Pharmaceuticals. (Basel)"},{"key":"10.1016\/j.pdpdt.2024.104430_bib0029","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s40942-017-0068-9","article-title":"Impact of image quality on OCT angiography based quantitative measurements","volume":"3","author":"Al-Sheikh","year":"2017","journal-title":"Int. J. Retina Vitreous."},{"key":"10.1016\/j.pdpdt.2024.104430_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2023.101206","article-title":"Optical coherence tomography angiography in diabetic retinopathy","volume":"97","author":"Waheed","year":"2023","journal-title":"Prog. Retin. Eye Res."},{"issue":"7","key":"10.1016\/j.pdpdt.2024.104430_bib0031","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/j.ophtha.2017.02.006","article-title":"Impact of multiple en face image averaging on quantitative assessment from optical coherence tomography angiography images","volume":"124","author":"Uji","year":"2017","journal-title":"Ophthalmology."},{"issue":"8","key":"10.1016\/j.pdpdt.2024.104430_bib0032","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1097\/IAE.0000000000000521","article-title":"Subthreshold Micropulse yellow laser versus subthreshold micropulse infrared laser in center-involving diabetic macular edema: morphologic and functional safety","volume":"35","author":"Vujosevic","year":"2015","journal-title":"Retina"},{"issue":"1","key":"10.1016\/j.pdpdt.2024.104430_bib0033","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ophtha.2022.08.012","article-title":"Diabetic macular edema and diode subthreshold micropulse laser: a randomized double-masked noninferiority clinical trial","volume":"130","author":"Lois","year":"2023","journal-title":"Ophthalmology."},{"issue":"3","key":"10.1016\/j.pdpdt.2024.104430_bib0034","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/s41433-019-0522-z","article-title":"Relationship between duration and extent of oedema and visual acuity outcome with ranibizumab in diabetic macular oedema: a post hoc analysis of Protocol I data","volume":"34","author":"Sadda","year":"2020","journal-title":"Eye (Lond)"},{"issue":"10","key":"10.1016\/j.pdpdt.2024.104430_bib0035","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1167\/tvst.9.10.31","article-title":"Subthreshold micropulse laser in diabetic macular edema: 1-year improvement in OCT\/OCT-angiography biomarkers","volume":"9","author":"Vujosevic","year":"2020","journal-title":"Transl Vis Sci Technol."},{"issue":"5","key":"10.1016\/j.pdpdt.2024.104430_bib0036","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1097\/IAE.0000000000003711","article-title":"Comparing functional and vascular layer outcomes of laser photocoagulation versus subthreshold micropulse laser for diabetic macular edema: an oct-angiography study","volume":"43","author":"Li","year":"2023","journal-title":"Retina"},{"key":"10.1016\/j.pdpdt.2024.104430_bib0037","doi-asserted-by":"crossref","DOI":"10.1007\/s00417-024-06558-y","article-title":"Anti-VEGF therapy for the long-term management of diabetic macular edema: a treat-to-target strategy based on macular morphology","author":"Nakao","year":"2024","journal-title":"Graefes. Arch. Clin. Exp. Ophthalmol."},{"issue":"11","key":"10.1016\/j.pdpdt.2024.104430_bib0038","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1007\/s00417-022-05703-9","article-title":"Intravitreal aflibercept for diabetic macular edema in real-world clinical practice in Japan: 24-month outcomes","volume":"260","author":"Sugimoto","year":"2022","journal-title":"Graefes. Arch. Clin. Exp. Ophthalmol."}],"container-title":["Photodiagnosis and Photodynamic Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1572100024004666?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1572100024004666?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T12:17:41Z","timestamp":1739017061000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1572100024004666"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":38,"alternative-id":["S1572100024004666"],"URL":"https:\/\/doi.org\/10.1016\/j.pdpdt.2024.104430","relation":{},"ISSN":["1572-1000"],"issn-type":[{"value":"1572-1000","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of one-year real-world outcomes between red (670 nm) subthreshold micropulse laser treatment and intravitreal aflibercept injection for treatment-na\u00efve diabetic macular edema","name":"articletitle","label":"Article Title"},{"value":"Photodiagnosis and Photodynamic Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pdpdt.2024.104430","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104430"}}